patterns to detect cancer early. DD’s tech scans blood for specific proteins that form unique patterns from a series of sixteen biomarkers, including Protein Kinase A (PKA), which appears at disease onset, and structural changes in the protein that activate a person's immune response. The patented method can detect cancer as early as Stage I in breast, lung, colorectal, ovarian, and pancreatic cancers with high accuracy. And, because DD analyzes proteins and not expensive (to process) DNA, it can deliver affordability to satisfy both clinical and consumer needs. In breast cancer testing, the technology delivers an unprecedented 99% Sensitivity and 97% Specificity as early as Stage I, which could eliminate over 90% of wasteful and unnecessary testing and biopsies from false positives. In lung, colorectal, pancreatic, and ovarian cancers, early data = 99% sensitivity, 98-99% Specificity (including at Stage I). 98% Tissue of Origin.

Definitive Diagnostics has been named a winner in the prestigious 2025 NYU Entrepreneurs Challenge, hosted by the NYU Stern Berkley Center for Entrepreneurship.